Escugen Biotechnology | ApexOnco - Clinical Trials news and analysis

x

“The team is super responsive to my inquiries and suggestions”

Chief Business Officer

US public biotech company

Click here for more information

Conferences Trial results

22 July 2024

ESMO 2024 preview – conjugates in the spotlight

Early attention falls on ADCs originated by ProfoundBio, SystImmune, MediLink and Seagen.

Conferences Trial results

10 December 2023

ASH 2023 – lupus target could work in lymphoma too

Subscribe to Escugen Biotechnology